Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Alprazolam Extended-Release Tablets 0.5mg, 1mg, 2mg, and 3mg. With this, the company has a total of 137 ANDA approvals (107 Final approvals and 30 tentative approvals) from USFDA.
Alprazolam Extended-Release Tablets 0.5mg, 1mg, 2mg, and 3mg is the generic equivalent to the reference listed drug Xanax XR Tablets 0.5mg, 1mg, 2mg, and 3mg of Pharmacia and Upjohn. The tablets are indicated for the treatment of panic disorder, with or without agoraphobia and fall under the Central Nervous System (CNS) therapeutic segment. The product has a market size of approximately $26.5 million for the twelve months ending September 2010, according to IMS and will be launched soon.
Aurobindo Pharma headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: